GOSS: CEO Hasnain Faheem Receives 437,500 Performance Units, Vesting on NDA Approval

Rhea-AI Filing Summary

Hasnain Faheem, President & CEO and a director of Gossamer Bio, Inc. (GOSS), reported a non‑derivative acquisition dated 10/01/2025 of 437,500 performance stock units at a reported price of $0. After the award, the filing shows 557,793 shares beneficially owned directly and 5,408,073 shares beneficially owned indirectly through a family trust. The performance stock units will vest in full upon the earlier of the approval of a new drug application for seralutinib or a change in control, in either case on or before the fourth anniversary of the grant date, and are subject to the reporting person’s continuous service to the issuer. The Form 4 was signed on 10/02/2025 by an attorney‑in‑fact.

Positive

• 437,500 performance stock units granted to the CEO on 10/01/2025
• Post‑grant beneficial ownership increased to 557,793 direct and 5,408,073 indirect shares
• Vesting tied to concrete milestones: NDA approval for seralutinib or a change in control (within four years)

Negative

• None.

Insights

Corporate Governance / Insider Transactions

Insider award increases CEO's direct and indirect holdings and ties vesting to an NDA approval or change in control.

The filing shows a 437,500 performance stock unit grant to Hasnain Faheem dated 10/01/2025, recorded at $0. Following the grant, reported beneficial ownership is 557,793 shares direct and 5,408,073 shares indirect via a family trust.

The award's vesting is explicitly conditioned on the earlier of approval of an NDA for seralutinib or a change in control, each occurring on or before the fourth anniversary of the grant date, and requires continuous service. Monitor the NDA approval milestone or any announced change in control as clear vesting triggers.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hasnain Faheem

(Last) (First) (Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A		437,500(1)	A	$0	557,793	D
Common Stock								5,408,073	I	By family trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer.

Remarks:

	/s/ Jeff Boerneke, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Hasnain Faheem report on Form 4 for GOSS?

He reported the acquisition of 437,500 performance stock units dated 10/01/2025 at a reported price of $0.

How many GOSS shares does Hasnain Faheem beneficially own after the grant?

The filing shows 557,793 shares beneficially owned directly and 5,408,073 shares beneficially owned indirectly through a family trust.

What are the vesting conditions for the performance stock units?

The units vest in full upon the earlier of approval of a new drug application for seralutinib or a change in control, on or before the fourth anniversary of the grant, subject to continuous service.

When was the Form 4 signed and filed?

The transaction date is 10/01/2025 and the Form 4 bears a signature dated 10/02/2025 by an attorney‑in‑fact.

What role does Hasnain Faheem hold at Gossamer Bio?

He is reported as President & CEO and a Director of Gossamer Bio.